ACE-i vs sartany w niewydolności serca: wyniki najnowszej meta-analizy

Chenhui Tai i wsp. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis
of randomized controlled trials. BMC Cardiovasc Disord. (2017) 17:257 (dostępny pełen tekst)

Conclusions: In HF patients, ACEIs, but not ARBs reduced all-cause mortality and cardiovascular deaths. Thus, ACEIs should be considered as first-line therapy to limit excess mortality and morbidity in this population.
5 października 2017